openPR Logo
Press release

Replimune Group, Inc. (NASDAQ: REPL) Investor Alert: Deadline in Lawsuit on September 22, 2025

A Deadline is coming up on September 22, 2025 in the lawsuit for certain investors in Replimune Group, Inc. (NASDAQ: REPL).

A Deadline is coming up on September 22, 2025 in the lawsuit for certain investors in Replimune Group, Inc. (NASDAQ: REPL).

A deadline is coming up on September 22, 2025 in the lawsuit filed for certain investors of Replimune Group, Inc. (NASDAQ: REPL) over alleged securities laws violations by Replimune Group, Inc.

Investors who purchased shares of Replimune Group, Inc. (NASDAQ: REPL) have certain options and there are strict and short deadlines running. Deadline: September 22, 2025. Replimune Group, Inc. (NASDAQ: REPL) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

According to the complaint filed in the U.S. District Court for the District of Massachusetts the plaintiff alleges on behalf of purchasers of Replimune Group, Inc. (NASDAQ: REPL) common shares between November 22, 2024 and July 21, 2025, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between November 22, 2024 and July 21, 2025, the misleading statements and/or failed to disclose that the Defendants recklessly overstated the IGNYTE trial's prospects, given material issues that defendants knew or should have known of, which resulted in the FDA deeming the IGNYTE trial inadequate and not well-controlled, and that as a result, defendants' statements about Replimune's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all times

Those who purchased shares of Replimune Group, Inc. (NASDAQ: REPL) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Replimune Group, Inc. (NASDAQ: REPL) Investor Alert: Deadline in Lawsuit on September 22, 2025 here

News-ID: 4176547 • Views:

More Releases from Shareholders Foundation, Inc.

Novo Nordisk A/S (NYSE: NVO) Long Term Investor Alert: Investigation of potential Wrongdoing
Novo Nordisk A/S (NYSE: NVO) Long Term Investor Alert: Investigation of potentia …
An investigation on behalf of current long-term investors in shares of Novo Nordisk A/S (NYSE: NVO) concerning potential breaches of fiduciary duties by certain directors and officers was announced. Investors who are current long term investors in Novo Nordisk A/S (NYSE: NVO) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for long term investors in
Lawsuit filed for Investors who lost money with shares of Fortinet, Inc. (NASDAQ: FTNT)
Lawsuit filed for Investors who lost money with shares of Fortinet, Inc. (NASDAQ …
An investor, who purchased shares of Fortinet, Inc. (NASDAQ: FTNT), filed a lawsuit over alleged violations of Federal Securities Laws by Fortinet, Inc. in connection with certain allegedly false and misleading statements. Investors who purchased shares of Fortinet, Inc. (NASDAQ: FTNT) have certain options and for certain investors are short and strict deadlines running. Deadline: November 21, 2025. NASDAQ: FTNT investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858)
CTO Realty Growth, Inc. (NYSE: CTO) Investor Alert: Deadline in Lawsuit on October 07, 2025
CTO Realty Growth, Inc. (NYSE: CTO) Investor Alert: Deadline in Lawsuit on Octob …
A deadline is coming up on October 07, 2025in the lawsuit filed for certain investors of CTO Realty Growth, Inc. (NYSE: CTO) over alleged securities laws violations by CTO Realty Growth, Inc. Investors who purchased shares of CTO Realty Growth, Inc. (NYSE: CTO) have certain options and there are strict and short deadlines running. Deadline: October 07, 2025. CTO Realty Growth, Inc. (NYSE: CTO) stockholders should contact the Shareholders Foundation at
Alert: Lawsuit filed for Investors who lost money with shares of Jasper Therapeutics, Inc. (NASDAQ: JSPR)
Alert: Lawsuit filed for Investors who lost money with shares of Jasper Therapeu …
An investor, who purchased shares of Jasper Therapeutics, Inc. (NASDAQ: JSPR), filed a lawsuit over alleged violations of Federal Securities Laws by Jasper Therapeutics, Inc. in connection with certain allegedly false and misleading statements. Investors who purchased shares of Jasper Therapeutics, Inc. (NASDAQ: JSPR) have certain options and for certain investors are short and strict deadlines running. Deadline: November 18, 2025. NASDAQ: JSPR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com

All 5 Releases


More Releases for Replimune

Lawsuit filed for Investors who lost money with shares of Replimune Group, Inc. …
An investor, who purchased shares of Replimune Group, Inc. (NASDAQ: REPL), filed a lawsuit over alleged violations of Federal Securities Laws by Replimune Group, Inc. in connection with certain allegedly false and misleading statements. Investors who purchased shares of Replimune Group, Inc. (NASDAQ: REPL) have certain options and for certain investors are short and strict deadlines running. Deadline: September 22, 2025. NASDAQ: REPL investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com
Nonmelanoma Skin Cancer Market to Reach New Heights in Growth by 2034, DelveInsi …
The Key Nonmelanoma Skin Cancer Companies in the market include - Genentech, Sanofi, Sirnaomics, AiViva BioPharma, Replimune, Ortho Dermatologics, Philogen S.p.A., AstraZeneca, Pfizer, and others. DelveInsight's "Nonmelanoma Skin Cancer Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Nonmelanoma Skin Cancer, historical and forecasted epidemiology as well as the Nonmelanoma Skin Cancer market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and
Cutaneous Squamous Cell Carcinoma Treatment Market Size Report 2034 | Incyte Cor …
DelveInsight's "Cutaneous Squamous Cell Carcinoma Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of Cutaneous Squamous Cell Carcinoma (CSCC), historical and forecasted epidemiology as well as the Cutaneous Squamous Cell Carcinoma (cSCC) market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan. Discover Key Insights into the Cutaneous Squamous Cell Carcinoma Market with DelveInsight's In-Depth Report @ Cutaneous
Oncolytic Viruses Market Expected to rise, 2034 | Targovax, Replimune, Genelux C …
DelveInsight's report titled "Oncolytic Virus Market Size, Target Population, Competitive Landscape, and Market Forecast - 2034" provides a comprehensive analysis of Oncolytic Virus Therapies, including historical data, the competitive market, and market trends across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The Oncolytic Viruses market growth is driven by factors like increase in the prevalence of Oncolytic Viruses, investments in research and development, entry
Oncolytic Virus Therapies Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals …
Oncolytic Virus Therapy companies working in the market are Targovax, Replimune, Genelux Corporation, Candel Therapeutics, DNAtrix, SillaJen, Treovir, Lokon Pharma AB, Istari Oncology, CG Oncology, Amgen, Daiichio Sankyo and others. (Albany, USA) DelveInsight's Oncolytic Virus Therapies Market Insights report includes a comprehensive understanding of current treatment practices, Oncolytic Virus Therapies emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the
Gene therapy Competitive Landscape Report 2024 (Updated) | Candel Therapeutics, …
DelveInsight's, "Gene Therapy Competitive Landscape 2024" report provides comprehensive insights about 250+ Gene Therapy companies and 300+ Gene Therapy drugs in the Gene therapy Competitive landscape. It covers the Gene Therapy therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Key Takeaways from the Gene Therapy Competitive Landscape Report DelveInsight's Gene Therapy report depicts a robust space with